Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer.

Kohei HashimotoYasuhide MiyoshiTetsuya ShindoMasakazu HoriYasumasa TsuboiKo KobayashiFumimasa FukutaToshiaki TanakaShintaro MiyamotoTakeshi MaehanaManabu OkadaNaotaka NishiyamaMasahiro YanaseRyuichi KatoHiroshi HottaYasuharu KunishimaAtsushi TakahashiShiro HinotsuKoh-Ichi SakataHiroshi KitamuraHiroji UemuraNaoya Masumori

Published in: Cancer medicine (2020)

Risk assessment in combination with dynamic changes of bone metastasis and PSADT determines the bone-predominant metastasis type to benefit from Ra-223.

Keyphrases

bone mineral density
risk assessment
soft tissue
bone loss
bone regeneration
postmenopausal women
rheumatoid arthritis
systemic sclerosis